Related Experiment Video
Updated: Nov 6, 2025
Production of High-Titer Recombinant Newcastle Disease Virus from Allantoic Fluid
Published on: May 25, 2022
Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus
Qiuxing Meng1, Jian He1, Liping Zhong1
1National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Bio-targeting Theranostics, Guangxi Medical University, Nanning, Guangxi, China.
Abstract:
This article reviews the preclinical research, clinical application and development of Newcastle disease virus (NDV) in the field of cancer therapy. Based on the distinctive antitumour properties of NDV and its positive interaction with the patient's immune system, this biologic could be considered a major breakthrough in cancer treatment. On one hand, NDV infection creates an inflammatory environment in the tumour microenvironment, which can directly activate NK cells, monocytes, macrophages and dendritic cells and promote the recruitment of immune cells. On the other hand, NDV can induce the upregulation of immune checkpoint molecules, which may break immune tolerance and immune checkpoint blockade resistance. In fact, clinical data have shown that NDV combined with immune checkpoint blockade can effectively enhance the antitumour response, leading to the regression of local tumours and distant tumours when injected, and this effect is further enhanced by targeted manipulation and modification of the NDV genome. At present, recombinant NDV and recombinant NDV combined with immune checkpoint blockers have entered different stages of clinical trials. Based on these studies, further research on NDV is warranted.
Insights
Newcastle disease virus (NDV) shows promise as an cancer therapy by activating immune cells and overcoming resistance to immune checkpoint blockade. Further research into NDV is warranted for its potential in cancer treatment.
Area of Science:
- Oncolytic virotherapy
- Immunotherapy
- Virology
Background:
- Newcastle disease virus (NDV) exhibits unique antitumor properties.
- NDV interacts positively with the patient's immune system, suggesting potential in cancer treatment.
Purpose of the Study:
- To review preclinical research, clinical applications, and development of NDV in cancer therapy.
- To explore NDV's mechanisms in modulating the tumor microenvironment and immune response.
Main Methods:
- Review of preclinical studies on NDV's anticancer effects.
- Analysis of clinical data on NDV in cancer treatment, including combination therapies.
- Examination of NDV's role in immune cell activation and immune checkpoint modulation.
Main Results:
- NDV infection induces an inflammatory tumor microenvironment, activating immune cells like NK cells, monocytes, macrophages, and dendritic cells.
- NDV upregulates immune checkpoint molecules, potentially overcoming immune tolerance and resistance to checkpoint blockade.
- Clinical data indicate that NDV combined with immune checkpoint blockade enhances antitumor responses, leading to tumor regression.
Conclusions:
- NDV represents a potential breakthrough in cancer therapy due to its oncolytic and immunomodulatory effects.
- Recombinant NDV and combination therapies are progressing through clinical trials.
- Further investigation into NDV-based cancer therapies is strongly recommended.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...